Ferring Ventures SA has secured a European patent publication (EP3676614A1) for novel methods of detecting regulatory T-cells expressing BTNL8. The patent application covers detection methods and associated pharmaceutical compositions for therapeutic use. Key IPC classifications span immunological assay methods (G01N 33/569), nucleic acid-based detection (C12Q 1/6883), and multiple therapeutic compositions (A61K 40/11 through A61K 40/41). The designated states include all major European markets.

This patent publication does not impose compliance obligations on third parties. Competitors in the immuno-oncology or autoimmune therapeutic space should review the claims to assess potential freedom-to-operate implications for their own diagnostic or therapeutic development programs. No immediate regulatory action is required.